Tc-TECANT1

Phase 1Small molecule

JJagiellonian University

Tc-TECANT1 is one of 50 small molecule programs targeting Neuroendocrine Neoplasm. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuroendocrine NeoplasmActive, not recruiting

Neuroendocrine NeoplasmPhase 1

Active, not recruiting

Competition

Competitive Landscape

50 competitors in Neuroendocrine Neoplasm

#DrugCompanyPhaseTrials

Afinitor

Kisqali

Arava

Lenvima

Lynparza

Talzenna

Nolvadex

Sandostatin

Lithobid

SSolvay Pharmaceuticals

Signifor

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neuroendocrine Neoplasm1 trial

Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms

Completed·JJagiellonian University·Phase 1·NCT05871320·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tc-TECANT1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tc-TECANT1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tc-TECANT1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jagiellonian University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: JJagiellonian University

Tc-TECANT1

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neuroendocrine Neoplasm1 trial

References

Drug Info

Quick Facts

Related News